Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference
| Poster presentation details: | |||
| Poster Title: | The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable as Assessed by the Thrombin Generation Test in Hemophilia A Plasma (Abstract #1112) |
||
| Presenting Author: | Tom Knudsen, DVM, Ph.D., senior director, translational research, Catalyst Biosciences | ||
| Date/Time: | Saturday, December 7, 2019 / 5:30 – 7:30 pm ET | ||
| Location: | Orange County Convention Center, Hall B | ||
| Poster Title: | Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice (Abstract #2420) |
||
| Presenting Author: | Tom Knudsen, DVM, PhD, senior director, translational research, Catalyst Biosciences | ||
| Date/Time: | Sunday, December 8, 2019 / 6:00 – 8:00 pm ET | ||
| Location: | Orange County Convention Center, Hall B | ||
A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website on the day of the presentation.
About
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst has engineered a portfolio of compounds that have increased potency over the naturally occurring proteases. Catalyst is focused on the field of hemostasis, including the subcutaneous treatment of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential uses and benefits of Catalyst’s products in development to address hemophilia indications. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect the Company’s ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s annual report filed with the Securities and Exchange Commission on March 8, 2019, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Investors and media
1.650.266.7144
investors@catbio.com
Source: Catalyst Biosciences, Inc.
